You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CpG55.2

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Influenza, Influenza Immunisation Trial in United States (AF03, Delta Inulin-CpG55.2, Influenza Virus Quadrivalent Inactivated

Completed
Has Results
  • Influenza
  • Influenza Immunisation
  • Atlanta, Georgia
  • +7 more
Dec 2, 2021

COVID-19 Trial in Adelaide (Advax-CpG55.2 adjuvanted recombinant spike protein)

Recruiting
  • COVID-19
  • Advax-CpG55.2 adjuvanted recombinant spike protein
  • Adelaide, South Australia, Australia
    ARASMI
Aug 15, 2022

Plague, Pneumonic, Plague, Vaccine-Preventable Diseases Trial in United States (rF1V vaccine and CpG 1018® adjuvant, rF1V

Recruiting
  • Plague, Pneumonic
  • +2 more
  • rF1V vaccine and CpG 1018® adjuvant
  • rF1V vaccine
  • Huntsville, Alabama
  • +4 more
Aug 16, 2022

SARS-CoV-2 Infection Trial in Australia (ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001))

Recruiting
  • SARS-CoV-2 Infection
  • ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)
  • Kanwal, New South Wales, Australia
  • +5 more
Nov 16, 2022

Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

Not yet recruiting
  • Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
    • (no location specified)
    Aug 23, 2023

    COVID-19 Trial in Semarang, Jakarta (SARS-CoV-2 protein subunit recombinant vaccine, SARS-CoV-2 inactivated vaccine)

    Active, not recruiting
    • COVID-19
    • SARS-CoV-2 protein subunit recombinant vaccine
    • SARS-CoV-2 inactivated vaccine
    • Semarang, Central Java, Indonesia
    • +1 more
    Aug 8, 2022

    SARS-CoV 2 Trial in Montréal, Québec (Intramuscular Vaccine)

    Completed
    • SARS-CoV 2
    • Intramuscular Vaccine
    • Montréal, Quebec, Canada
    • +1 more
    Apr 4, 2022

    Myeloid Malignancies, Lymphoid Malignancies Trial in Durham (NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001)

    Recruiting
    • Myeloid Malignancies
    • Lymphoid Malignancies
    • NK Cell enriched-DLI only
    • NK-DLI + DUK-CPG-001
    • Durham, North Carolina
      Duke University Health System
    Mar 8, 2022

    Prostate Cancer Trial in Beijing (2.0 GBq of 177Lu-EB-PSMA)

    Recruiting
    • Prostate Cancer
    • 2.0 GBq of 177Lu-EB-PSMA
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    Jul 13, 2022

    COVID-19 Trial in Nedlands (SCB-2019, SCB-2019 with AS03 adjuvant, SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant)

    Completed
    • COVID-19
    • SCB-2019
    • +3 more
    • Nedlands, Western Australia, Australia
      Linear Clinical Research Ltd
    Feb 17, 2022

    COVID-19 Trial in Kyiv, Vinnitsa (CpG 1018/Alum-adjuvanted SCB-2019 vaccine, Havrix, Placebo; 0.9% saline)

    Terminated
    • COVID-19
    • CpG 1018/Alum-adjuvanted SCB-2019 vaccine
    • +2 more
    • Kyiv, Ukraine
    • +3 more
    May 19, 2022

    Primary CNS Lymphoma Trial in Paris (Glucarpidase, Methotrexate (MTX))

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Paris, France
      Hôpital Pitié-Salpêtrière
    Oct 24, 2022

    Blood Vessel Study

    Completed
    • Cardiovascular Disease
      • Research Triangle Park, North Carolina
        NIEHS Clinical Research Unit (CRU)
      Jan 25, 2023

      Meningococcal Meningitis Trial in Surabaya (batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4), batch 2 of

      Not yet recruiting
      • Meningococcal Meningitis
      • batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)
      • +3 more
      • Surabaya, Indonesia
        Husada Utama Hospital
      Nov 13, 2023

      Hypercapnia Trial in Jiaxing (mild hypercapnia, normocapnia)

      Recruiting
      • Hypercapnia
      • mild hypercapnia
      • normocapnia
      • Jiaxing, Zhejiang, China
        Affiliated Hospital of Jiaxing University
      Apr 3, 2023

      Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV Trial in Tampa (IFx-Hu2.0)

      Completed
      Has Results
      • Cutaneous Melanoma, Stage III
      • Cutaneous Melanoma, Stage IV
      • IFx-Hu2.0
      • Tampa, Florida
        H. Lee Moffitt Cancer Center
      Aug 5, 2022

      COVID-19 Infection, COVID-19 Vaccine Adverse Reaction Trial in Seoul (LEM-mR203, Placebo)

      Not yet recruiting
      • COVID-19 Infection
      • COVID-19 Vaccine Adverse Reaction
      • LEM-mR203
      • Placebo
      • Seoul, Korea, Republic of
        Seoul National University Hospital Clinical Trials Center
      Sep 12, 2023

      COVID-19 Trial in Barranquilla, Cali (Candidate vaccine, SCB-2019)

      Not yet recruiting
      • COVID-19
      • Candidate vaccine, SCB-2019
      • Barranquilla, Colombia
      • +1 more
      Aug 23, 2022

      Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Merkel Cell Carcinoma Trial (IFx-Hu2.0)

      Available
      • Cutaneous Melanoma, Stage III
      • +3 more
      • IFx-Hu2.0
      • (no location specified)
      Aug 5, 2022

      Multiple Sclerosis Trial in Cambridge (GSK3888130B, Placebo)

      Recruiting
      • Multiple Sclerosis
      • Cambridge, United Kingdom
        GSK Investigational Site
      Dec 22, 2022

      SARS-CoV-2 Trial in United States (mRNA-1283, mRNA-1273, Placebo)

      Active, not recruiting
      • SARS-CoV-2
      • mRNA-1283
      • +2 more
      • Chandler, Arizona
      • +4 more
      Sep 22, 2022

      Chronic Pain After Breast Cancer Treatment.

      Not yet recruiting
      • Neoplasm, Breast
      • +2 more
      • Biomarkers
      • (no location specified)
      Aug 17, 2022

      Group B Streptococcal Infections Trial in Ghent (GBS-NN/NN2, Placebo)

      Recruiting
      • Group B Streptococcal Infections
      • GBS-NN/NN2
      • Placebo
      • Ghent, Belgium
        University Hospital Ghent - Centrum voor Vaccinologie (CEVAC) de
      Mar 21, 2023

      COVID-19 Trial in Bloemfontein, Pretoria, Soweto (Candidate vaccine, SCB-2020S, Candidate vaccine, SCB-2019, Squalene based

      Active, not recruiting
      • COVID-19
      • Candidate vaccine, SCB-2020S
      • +3 more
      • Bloemfontein, South Africa
      • +2 more
      Oct 18, 2022

      COVID-19 Trial in Semarang, Makassar, Padang (SARS-CoV-2 protein subunit recombinant vaccine, )

      Active, not recruiting
      • COVID-19
      • SARS-CoV-2 protein subunit recombinant vaccine
      • placebo
      • Semarang, Central Java, Indonesia
      • +2 more
      Aug 8, 2022